Nabriva Therapeutics AG Alpha and Beta Analysis
| NBRVDelisted Stock | USD 1.62 0.01 0.61% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Nabriva Therapeutics AG. It also helps investors analyze the systematic and unsystematic risks associated with investing in Nabriva Therapeutics over a specified time horizon. Remember, high Nabriva Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Nabriva Therapeutics' market risk premium analysis include:
Beta (0.23) | Alpha 0.14 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Nabriva |
Nabriva Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Nabriva Therapeutics market risk premium is the additional return an investor will receive from holding Nabriva Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Nabriva Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Nabriva Therapeutics' performance over market.| α | 0.14 | β | -0.23 |
Nabriva Therapeutics Fundamentals Vs Peers
Comparing Nabriva Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Nabriva Therapeutics' direct or indirect competition across all of the common fundamentals between Nabriva Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Nabriva Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Nabriva Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Nabriva Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Nabriva Therapeutics to competition |
| Fundamentals | Nabriva Therapeutics | Peer Average |
| Return On Equity | -2.69 | -0.31 |
| Return On Asset | -0.65 | -0.14 |
| Profit Margin | (1.48) % | (1.27) % |
| Operating Margin | (1.29) % | (5.51) % |
| Current Valuation | 3.29 M | 16.62 B |
| Shares Outstanding | 3.2 M | 571.82 M |
| Shares Owned By Insiders | 0.96 % | 10.09 % |
Nabriva Therapeutics Opportunities
Nabriva Therapeutics Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Risk factors for SARS-CoV-2 seropositivity in a health care worker ... - BMC Infectious Diseases | 05/16/2023 |
2 | Exploring of Industrial Microbiology Market Size Likely to be valued ... - Medgadget | 05/25/2023 |
3 | Antibiotic Resistance Market 2023 SWOT Analysis, Competitive ... - KaleidoScot | 06/08/2023 |
4 | Global Pneumonia Therapeutics Market Size and Forecast Pfizer ... - Reedley Exponent | 06/15/2023 |
5 | Siemens Healthineers, Thermo Fisher, Becton Dickinson, Roche ... - 360Dx | 07/12/2023 |
6 | Antibiotic Resistance Market Expected to High Growth over the ... - Chatfield News-Record | 07/19/2023 |
About Nabriva Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Nabriva or other delisted stocks. Alpha measures the amount that position in Nabriva Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Nabriva Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Nabriva Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Nabriva Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Nabriva Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Nabriva Therapeutics. Please utilize our Beneish M Score to check the likelihood of Nabriva Therapeutics' management manipulating its earnings.
| 2nd of August 2023 Upcoming Quarterly Report | View | |
| 30th of June 2023 Next Fiscal Quarter End | View |
Build Portfolio with Nabriva Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Nabriva Stock
If you are still planning to invest in Nabriva Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nabriva Therapeutics' history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |